SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Zouater Hichem)
 

Sökning: WFRF:(Zouater Hichem) > Safety and effectiv...

Safety and effectiveness of replacement with biosimilar growth hormone in adults with growth hormone deficiency: results from an international, post-marketing surveillance study (PATRO Adults).

Höybye, Charlotte (författare)
Karolinska Institutet
Beck-Peccoz, Paolo (författare)
Murray, Robert D (författare)
visa fler...
Simsek, Suat (författare)
Stalla, Günter (författare)
Strasburger, Christian J (författare)
Urosevic, Dragan (författare)
Zouater, Hichem (författare)
Johannsson, Gudmundur, 1960 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition,Institute of Medicine, Department of Internal Medicine and Clinical Nutrition
visa färre...
 (creator_code:org_t)
2021-03-20
2021
Engelska.
Ingår i: Pituitary. - : Springer Science and Business Media LLC. - 1573-7403 .- 1386-341X. ; 24:4, s. 622-629
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • To evaluate safety and effectiveness of biosimilar recombinant human growth hormone (rhGH; Omnitrope®) in adults with growth hormone deficiency (GHD), using data from the PATRO Adults study.PATRO Adults was a post-marketing surveillance study conducted in hospitals and specialized endocrinology units across Europe. The primary objective was to assess the safety of rhGH in adults treated in routine clinical practice. All adverse events (AEs) were monitored and recorded for the complete duration of Omnitrope® treatment. Effectiveness was evaluated as a secondary objective.As of January 2020, 1447 patients (50.9% male) had been enrolled from 82 centers in 9 European countries. Most patients had adult-onset GHD (n=1179; 81.5%); 721 (49.8%) were rhGH-naïve at study entry. Overall, 1056 patients (73.0%) reported adverse events (AEs; n=5397 events); the majority were mild-to-moderate in intensity. Treatment-related AEs were reported in 117 patients (8.1%; n=189 events); the most commonly reported (MedDRA preferred terms) were arthralgia (n=19), myalgia (n=16), headache (n=14), and edema peripheral (n=10). In total, 495 patients (34.2%) had serious AEs (SAEs; n=1131 events); these were considered treatment-related in 28 patients (1.9%; n=35 events). Mean (standard deviation) IGF-I SDS increased from - 2.34 (1.47) at baseline to - 0.23 (1.65) at 12months, and remained relatively stable thereafter (up to 3years). Body mass index remained stable between baseline and 3years.Data from PATRO Adults indicate biosimilar rhGH (Omnitrope®) is not associated with any unexpected safety signals, and is effective in adults with GHD treated in real-world clinical practice.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

  • Pituitary (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy